Kornimate/medical-research-clean huggingface dataset:
testing the effects of a text message caregiver support intervention for latinos

Conditions: Alzheimer Disease

Summary: the goal of this randomized clinical trial it to test the efficacy of cuidatext, the first alzheimer's disease and related dementias (adrd) caregiver support intervention to capitalize on text messaging, among latinos. researchers will compare those who receive the cuidatext intervention to those who do not receive the intervention to see if cuidatext effects latino caregiver stressors and their negative consequences . participants will receive a variety of text messages, from automatic to keyword-drive, regarding adrd education, social support, self-care, adrd care management, and behavioral symptoms. participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.


Eligibility criteria:
inclusion criteria: * over the age of 18 * spanish and english-speaking people who identify as latino * reports providing hands-on care for a relative who has been given a clinical or research adrd diagnosis and has an eight-item informant interview to differentiate aging and dementia (ad-8) screening score ≥2, indicating cognitive impairment * has a score of 7 or higher on the 10-item center for epidemiologic studies depression scale (cesd-10) * self-reports being able to read and write * owns a cell phone with a flat fee, and uses it at least weekly for texting. exclusion criteria: * participation in another wellbeing-related clinical trial * cohabitation with another participant in the cuidatext r01 study * participants who provide care for a person with adrd already cared for by another participant in the cuidatext r01 study * participant plans to move to another country within seven months
role of ginkgo biloba extract in iugr

Conditions: Intrauterine Growth Restriction (IUGR)

Summary: the use of herbal medicinal products is increasing enormously in recent years, mainly among women, who use them for the most varied purposes, such as in menstrual problems, menopausal symptoms, mood disturbances and to strengthen their bones. most of these benefits are due to the flavonoids present in these products. these flavonoids have anticarcinogenic, antiviral, antioxidant and antiinflammatory activities, as well as being used in the treatment of osteoporosis, menopausal symptoms and cardiovascular diseases . besides the benefits from the consumption of flavonoids, little is known about their safety and potentially harmful toxic effects, such as mutagenicity and genotoxicity which might occur if taken in large doses . safety of ginkgo biloba during pregnancy or lactation was not criticized in literature. roasted and raw ginkgo seed were not reported in the evidence-based medicine literature as being either safe or contraindicated in pregnancy or lactation. a higher incidence of postpartum hemorrhage was reported in the literature when associated with a 3-month ingestion of ginkgo biloba extract. flavonoids are components of ginkgo biloba l. (ginkgoaceae), a medicinal plant widely used by the population . g. biloba has its origin in china, korea and japan where its fruits and leaves have been used as food and medicine for a long time. the extract of g. biloba (egb) is composed of different terpene trilactones, i.e., ginkgolides a, b, c, j and bilobalide, many flavonol glycosides, biflavones and alkylphenols . the major flavonoids in the extract are kaempferol, quercetin and isorhamnetin\] whose metabolites were found in the blood of rats and in human urine after oral administration of egb. due to its actions as an anti-inflammatory and antioxidant, egb has been largely used in the treatment of alzheimer's disease, pre-menstrual syndrome, cerebrovascular insufficiency and peripheral arterial occlusive disease . in folk medicine, egb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema . the aim of this study was to evaluate the effect of oral supplementation of ginkgo biloba extract on the fetal weight as well as feto-maternal blood flow in cases of intrauterine growth restriction.


Eligibility criteria:
inclusion criteria: * pregnant women in their third trimester (28-30 weeks of gestation). * pregnant women whose pregnancy was complicated with intra uterine growth restriction (iugr). * normal doppler indices in uterine, umbilical and middle cerebral arteries at time of recruitment. exclusion criteria: * multiple pregnancies, * hypertension, * fetal congenital anomalies, * previous history of congenital anomalies or chromosomal abnormalities. * diabetes mellitus * premature pre-labor rupture of membranes * antepartum hemorrhage
intraoperative angiography using icg in rectal cancer patients to prevent anastamotic leak after laparoscopic anterior resection of the rectum

Conditions: Rectal Cancer

Summary: the study enrols patients with operative rectal cancer qualified for laparoscopic anterior resection. patients are given first dose of indocyanine green iv intraoperatively (icg) before choosing the appropriate site of the anastomosis, and the second dose after performing the anastomosis to confirm adequate blood supply to the anastomotis. the main outcome assessed is the frequency o anastomotic leak in comparison to the group of patients that do not undergo intraoperative icg angiography.


Eligibility criteria:
inclusion criteria: * operative rectal cancer exclusion criteria: * known allergy toward indocyanic green

Keywords: rectal cancer laparoscopic anterior resection intraoperative angiography icg
the effect of periodontal treatment on psoriasis

Conditions: Periodontal Diseases

Summary: there is a relationship between psoriasis and periodontal disease. this relationship may be double-sided.

the aim of this randomized controlled clinical study was to determine the effect of non-surgical mechanical periodontal treatment on psoriasis. the study population consisted of 92 periodontitis patients with psoriasis who had untreated periodontal disease. two randomized groups were formed from these patients. immediate periodontal treatment (test group, n = 46) and delayed periodontal treatment (control group, n = 46). clinical periodontal measures, saliva interleukin 2, interleukin 6 and secretory immunoglobulin a levels and pasi scores were performed at baseline and 8th week in control and test group.

Eligibility criteria:
inclusion criteria: * the presence at least 20 remaining teeth, * the presence of stage i or stage ii periodontitis, * the presence of diagnosed psoriasis. exclusion criteria: * patients who had the immune-inflammatory disease and require antibiotic prophylaxis, * patients who received periodontal treatment prior to 6 months, * women who were breastfeeding or pregnant, * patients using medicines such as antibiotics, anti-inflammatory drugs, immune-suppressants.

Keywords: psoriasis
face of sleepiness

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this pilot study is to find out whether successful treatment of obstructive sleep apnea makes people look less sleepy, for example by reducing swelling or dark circles under the eyes. in addition, this study will help determine whether facial photographs may be used to help identify patients who should be tested for sleep apnea and daytime sleepiness.

the main symptom of nocturnal sleep disorders is often excessive daytime sleepiness. although sleepiness can be a major contributor to decreased quality of life, and even mortality, patients frequently grow habituated to their sleepiness, ignoring it and any underlying disorder. one scarcely explored potential consequence that could motivate patients to address sleep disorders is a sleepy facial appearance. no peer-reviewed literature, to our knowledge, has explored whether inadequate or insufficient sleep actually causes changes facial appearance. no published literature has examined the extent to which treatment for sleep disorders might improve such facial changes, and perhaps motivate patients to treat their sleep disorders. to address these questions in a preliminary manner, therefore, the investigators propose to use cutting-edge photographic technology to assess subtle changes in facial appearance. the investigators will recruit 20 sleepy adult patients who are diagnosed with obstructive sleep apnea, an ideal disease model in which subjects can be tested before and after alleviation of severe sleepiness by home use of continuous positive airway pressure. results of this pilot study could show for the first time that successful treatment of a chronic sleep disorder improves facial features commonly perceived as an undesirable sign of sleepiness.

Eligibility criteria:
inclusion criteria: * adults, age 18-65 * recently diagnosed with obstructive sleep apnea, confirmed by polysomnography (sleep study) * experiencing daytime sleepiness, based on epworth sleepiness scale * scheduled for a positive airway pressure (pap) titration study (cpap or bipap) * willing to use cpap or bipap at pressures prescribed by the treating physician * willing to have facial photographs taken before treatment and 2-4 months after nightly use of cpap or bipap exclusion criteria: * diagnosed with other sleep, medical or psychiatric disorders that might limit the effectiveness of pap treatment (such as morbid obesity, emphysema, and neurodegenerative disorders) * conditions that may cause daytime sleepiness (such as narcolepsy, primary insomnia, seizure disorders, or major depression) * use of medications or herbal remedies that affect sleep and behavior * history of facial plastic or reconstructive surgery or botox injections or plans to undergo these types of treatments prior to completing the second study visit

Keywords: sleep apnea sleep disordered breathing cpap bipap treatment outcomes
tezepelumab copd exacerbation study

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2a study to explore the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (copd)

this is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (copd) receiving triple inhaled maintenance therapy, and having had 2 or more documented copd exacerbations in the 12 months prior to visit 1. approximately, 338 subjects will be randomized globally. subjects will be stratified by region and prior number of exacerbations (2 vs. 3 or more). subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52 week treatment period. the study also includes a post-treatment follow-up period of 12 weeks.

Eligibility criteria:
inclusion criteria: 1. history of moderate to very severe physician-diagnosed copd for at least 12 months prior to enrolment with a post-bronchodilator fev1/fvc\<0.70 and a post-bronchodilator fev1 ≥20% and ≤80% of predicted normal value. 2. history of at least 2 documented moderate to severe copd exacerbations within 2 to 52 weeks prior to enrollment. 3. cat score of ≥15 at enrollment and on day of randomization. 4. documented treatment with triple therapy for copd (medium or high dose ics/laba/lama) throughout the year prior to enrollment. the dose of ics should be stable for 3 months prior to enrollment. exclusion criteria: 1. clinically important pulmonary disease other than copd, as judged by the investigator (including current or historic asthma diagnosis). 2. any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious (including risk factors for pneumonia), endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable. 3. major surgery within 8 weeks before enrollment. 4. history of clinically significant infection requiring antibiotics or antiviral medication within 14 days before enrollment. 5. pregnant or breastfeeding. 6. the chest/lungs with pathology that precludes the patient's ability to complete the study 7. the patient has active covid 19 infection during screening period.

Keywords: copd moderate copd severe copd chronic obstructive pulmonary disease
does gender play a role in bone-mineral density measurement precision?

Conditions: Osteoporosis

Summary: bone mineral density (bmd) measurement using dual-energy x-ray absorptiometry (dxa) is the current gold standard for osteoporosis diagnosis and therapy monitoring. like all quantitative tests, there is some variability in bmd results obtained when scanning a person more than once. as such, it is current clinical practice, based on the recommendation of the international society for clinical densitometry, that each technologist perform a precision assessment. this approach consists of scanning 30 people twice; the data from which allow determination of what constitutes a real difference in bmd with 95% confidence. a precision assessment typically evaluates a specific clinic's population, using the age range and genders seen at that clinic. however men generally have larger, but often more arthritic, bones than women which may impact the precision results. therefore, it is possible that gender-specific precision values should be used in clinical practice, however this issue has never been investigated.


Eligibility criteria:
inclusion criteria: * age ≥ 65 years * able and willing to sign informed consent exclusion criteria: * inability to have dxa scans performed due to weight ≥ 450 pounds (exceeds densitometer table limit) * metallic hardware in, or overlaying, any of the measured skeletal sites
interest of the tool: evaluation of specific care in an ecological environment for patients suffering from schizophrenia-like disorders

Conditions: Patients With Schizophrenia-like Disorders

Summary: the study use a new ecological questionnaire called essme developed by a care team in order to evaluate ecological environment of patients with schizophrenia-like disorders. indeed, evaluation in an ecological environment would make it possible to be as close as possible to the concerns of theses patients, which could improve the care of this population, by making it possible to set with the patient objectives anchored in their daily life.

the duration of patient's participation to the study is 6 months plus 7 to 14 days. the study includes the following visits : * v0: inclusion visit (day 0) with the administration of standard of care questionnaires; * v1: visit at patient's home (day 0 +7 to 14 days) with the administration of the experimental essme questionnaire; * v2: follow-up visit at 6 months (m6) with the administration of the same standard of care questionnaires than at the inclusion visit; * v3: visit at patient's home (m6 + 7 to 14 days) with the administration of the experimental essme questionnaire.

Eligibility criteria:
inclusion criteria: * man or woman aged 18 to 65 inclusive; * diagnosis of schizophrenia or schizoaffective disorder according to the diagnostic and statistical manual of mental disorders version number 5 (dsm-v) criteria; * patient receiving care in a center for rehabilitation and intersectoral therapeutic activities (creativ); * person who consented to the study; * affiliate or beneficiary of a social security scheme. exclusion criteria: * patient aged under 18 or over 65; * pregnant or breastfeeding women; * person unable or unwilling to receive a home visit; * person not consenting to the study; * presence of a diagnosis of an associated neurodevelopmental disorder; * presence of a diagnosis of dementia or associated neurodegenerative process; * person with a level of french language insufficient to understand the items.
strength training after hip fracture surgery

Conditions: Hip Fracture

Summary: the purpose of this study is to examine the effect of progressive strength training of the fractured limb in patients with hip fracture, during admittance in an acute orthopedic ward. the primary study hypothesis is that the training will reduce the strength deficit in the fractured limb in comparison with the non-fractured limb. secondary, that patients following the intervention will present larger improvements in physical function compared to controls.


Eligibility criteria:
inclusion criteria: * primary hip fracture surgery * 65 years or older * speak and understand the danish language * able to give informed consent * home-dwelling with and independent prefracture indoor walking ability equal to new mobility score \>=2 exclusion criteria: * multiple fractures * weightbearing restrictions * patient unwilling to participate in appropriate rehabilitation * not able to cooperate to tests * terminal illness * patients who want an observer present at the information interview, but where such one is not available. * patients with a cervical hip fracture treated with total hip arthroplasty or hip pins, due to expected short length of hospital stay.

Keywords: strength deficit physical function
prevalence and factors associated with sarcopenia in pre-retirement aged adults with chronic non-specific lower back pain

Conditions: Sarcopenia; Chronic Lower Back Pain

Summary: to study the prevalence of sarcopenia in a pre-retirement group with chronic lower back pain and factors associated between sarcopenia and chronic lower back pain in the pre-retirement group.


Eligibility criteria:
inclusion criteria: 1. be a person between the ages of 50 - 59 years with or without chronic lower back pain longer than 3 months, but without any dangerous signs of lower back pain, sciatica pain, and neurological disorder. 2. be able to walk continuously for at least 10 minutes. 3. give written consent to join the research project. exclusion criteria: 1. have a history of spinal fracture, spondylolisthesis, scoliosis, or osteomyelitis. 2. have a neurological disorder or myasthenia gravis. 3. have a congenital disease such as acute coronary syndrome, cancer, or severe muscular or joint disease that affects the ability to walk continuously for at least 10 meters. 4. be implanted with a pacemaker or electrical device. 5. refuse or withdraw from the study.
survival in a randomized phase iii trial in patients with limited disease (ld) small cell lung cancer vaccinated with adjuvant bec2 and bcg

Conditions: Carcinoma, Small Cell Lung

Summary: this trial is designed to test the impact of adjuvant bec2 (2.5 mg)/bcg vaccination on survival in patients with ld small cell lung cancer (sclc). patients will be stratified by institution, kps (60 - 70% vs 80 - 100%), and response to first line combined modality therapy (cr vs pr) that consisted of at least a 2 drug regimen (4 - 6 cycles) and a chest radiotherapy regimen. patients will be randomized to one of two treatment arms: standard arm (observational cohort) or best supportive care, or the treatment arm (5 intradermal vaccinations of bec2 (2.5 mg) + bcg given on day 1 of weeks 0, 2, 4, 6, and 10.


Eligibility criteria:
inclusion criteria: * histo-cytologically proven sclc * limited disease at diagnosis * age greater than or equal to 18 * patients with a clinical response of cr or pr to first line combined modality therapy * kps greater than or equal to 60 * adequate bone marrow, liver and heart functions * written informed consent exclusion criteria: * prior surgical treatment for sclc * history of tuberculosis * ncic ctg grade 3 local skin toxicity reaction (ulceration) to \> iu ppd test \> 5 iu * hiv positive * splenectomy or spleen radiation therapy in medical history * prior therapy to proteins of murine origin * any second line therapy for sclc * investigational agent or immune therapy within 4 weeks prior to study randomization * severe active infections * active infections requiring systemic antibiotics, antiviral, or antifungal treatments * serious unstable chronic illness * the use of systemic anti-histamines, nsaid or systemic corticosteroids * any previous malignancy except adequately treated cis of the cervix or non melanoma skin cancer or if previous malignancy was more than 5 years prior and there are no signs of recurrence * pregnancy or breast feeding or absence of adequate contraception for fertile patients * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before randomization in the trial.

Keywords: ld small cell lung cancer bec2, vaccine adjuvant, monoclonal antibody ld small cell lung cancer (va classification, zelen, 1973)
survival outcomes of uterine cervical malignancies in chinese population

Conditions: Uterine Cervical Neoplasms; Survival

Summary: this study aims to determine survival outcomes (overall survival and progression-free survival) of primary malignancies of uterine cervix in china and relevant risk factors in a prospective cohort study.


Eligibility criteria:
inclusion criteria: * primary malignancies of uterine cervix. exclusion criteria: * secondary malignancies of uternie cervix.
promacta pregnancy registry

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Summary: since idiopathic thrombocytopenic purpura (itp) affects women who are of reproductive capacity and taking into account the lack of data concerning eltrombopag (promacta) use during pregnancy, the eltrombopag (promacta) registry will be an essential component of the ongoing risk management for eltrombopag (promacta). the registry will detect and record the events (live births, spontaneous abortions, stillbirths, elective terminations, therapeutic terminations, any serious pregnancy outcome, major and minor congenital anomalies, outcomes including preterm, small for gestation age, or intrauterine growth restriction adverse adverse effects on the following: immune system development, platelet number and function, neoplasm formation, bone marrow reticulin formation, thrombotic events) in the mother and/or the neonate/infant. the adverse events in the infant will be assessed through at least the first year of life. the pregnancy registry will compare the pregnancy and fetal outcomes of women exposed to eltrombopag tablets during pregnancy to an unexposed control population. this study will be a prospective observational, exposure follow-up study.

the outcomes of pregnancy are: live births, spontaneous abortions, stillbirths, elective terminations, therapeutic terminations, any serious pregnancy outcome, major and minor congenital anomalies, outcomes including preterm, small for gestation age, or intrauterine growth restriction adverse effects on the following: immune system development, platelet number and function, neoplasm formation, bone marrow reticulin formation, thrombotic events in the mother and/or the neonate/infant.

Eligibility criteria:
inclusion criteria: documentation that eltrombopag is being taken during pregnancy. timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to eltrombopag for stratification and reporting purposes). sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered. whether the outcome of pregnancy was known at the time of the report. source of the report (i.e. health care professional, patient). full provider contact information to allow for follow-up (name, address, etc.) exclusion criteria: none

Keywords: thrombocytopenia pregnancy